Stock GNS GENUS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genus plc

Equities

GNS

GB0002074580

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:01 2024-04-26 am EDT 		5-day change 1st Jan Change
1,736 GBX +1.88% Intraday chart for Genus plc +1.05% -20.00%
Apr. 17 Gigantic marine reptile's fossils found by British girl and father RE
Mar. 08 Genus Power Infrastructures Forms New Subsidiary MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,707 2,285 3,221 1,634 1,417 1,138 - -
Enterprise Value (EV) 1 1,787 2,387 3,327 1,819 1,612 1,376 1,347 1,327
P/E ratio 223 x 57.1 x 68.9 x 40.3 x 42.9 x 48 x 27.4 x 20.6 x
Yield 1.05% 0.82% 0.65% 1.28% 1.48% 1.84% 1.99% 2.2%
Capitalization / Revenue 3.49 x 4.14 x 5.61 x 2.75 x 2.05 x 1.69 x 1.6 x 1.52 x
EV / Revenue 3.66 x 4.33 x 5.79 x 3.07 x 2.34 x 2.04 x 1.89 x 1.77 x
EV / EBITDA 23.6 x 24 x 31.5 x 18.2 x 14.6 x 13.1 x 11.2 x 10 x
EV / FCF 110 x 67.8 x 85.7 x -233 x 88.6 x 67.7 x 24.2 x 22.3 x
FCF Yield 0.91% 1.47% 1.17% -0.43% 1.13% 1.48% 4.14% 4.49%
Price to Book 3.32 x 4.51 x 6.48 x 2.84 x 2.47 x 1.96 x 1.88 x 1.77 x
Nbr of stocks (in thousands) 64,472 64,685 64,941 65,168 65,404 65,563 - -
Reference price 2 26.48 35.32 49.60 25.08 21.66 17.36 17.36 17.36
Announcement Date 9/5/19 9/8/20 9/9/21 9/8/22 9/7/23 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 488.5 551.4 574.3 593.4 689.7 674.6 711.7 748.8
EBITDA 1 75.6 99.3 105.5 99.9 110.6 105.3 120.5 132.6
EBIT 1 57.7 65.3 76.9 68.8 74.6 70.81 89.04 103.2
Operating Margin 11.81% 11.84% 13.39% 11.59% 10.82% 10.5% 12.51% 13.78%
Earnings before Tax (EBT) 1 9.9 51.5 55.8 48.4 39.4 36.9 60.65 75
Net income 1 7.8 40.5 47.3 40.9 33.3 24.9 43.25 53.9
Net margin 1.6% 7.34% 8.24% 6.89% 4.83% 3.69% 6.08% 7.2%
EPS 2 0.1190 0.6190 0.7200 0.6220 0.5050 0.3614 0.6332 0.8443
Free Cash Flow 1 16.3 35.2 38.8 -7.8 18.2 20.34 55.78 59.56
FCF margin 3.34% 6.38% 6.76% -1.31% 2.64% 3.01% 7.84% 7.95%
FCF Conversion (EBITDA) 21.56% 35.45% 36.78% - 16.46% 19.32% 46.28% 44.91%
FCF Conversion (Net income) 208.97% 86.91% 82.03% - 54.65% 81.67% 128.98% 110.51%
Dividend per Share 2 0.2770 0.2910 0.3200 0.3200 0.3200 0.3200 0.3449 0.3826
Announcement Date 9/5/19 9/8/20 9/9/21 9/8/22 9/7/23 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2024 S1
Net sales 1 270.7 333.6
EBITDA 47.4 -
EBIT 34.4 -
Operating Margin 12.71% -
Earnings before Tax (EBT) 30.4 -
Net income - -
Net margin - -
EPS 0.3630 -
Dividend per Share 2 0.0940 0.1030
Announcement Date 2/27/20 2/22/24
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 79.6 103 106 185 196 238 209 189
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.053 x 1.033 x 1.001 x 1.852 x 1.77 x 2.257 x 1.736 x 1.422 x
Free Cash Flow 1 16.3 35.2 38.8 -7.8 18.2 20.3 55.8 59.6
ROE (net income / shareholders' equity) 10% 11.1% 13.2% 10.1% 9.63% 7.72% 9.73% 11%
ROA (Net income/ Total Assets) 0.97% - - - - - - -
Assets 1 806.7 - - - - - - -
Book Value Per Share 2 7.980 7.840 7.650 8.850 8.770 8.850 9.230 9.830
Cash Flow per Share 2 0.5100 1.010 1.030 0.5200 0.7600 0.5500 0.9900 1.260
Capex 1 17.1 24.6 28.7 42.1 35.2 30.1 23.9 26.3
Capex / Sales 3.5% 4.46% 5% 7.09% 5.1% 4.47% 3.36% 3.51%
Announcement Date 9/5/19 9/8/20 9/9/21 9/8/22 9/7/23 - - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Genus plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
17.36 GBP
Average target price
29.62 GBP
Spread / Average Target
+70.59%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENUS PLC Stock Genus plc
-20.00% 1.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GNS Stock
  4. Financials Genus plc